EpCAM-Targeted Antibodies Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

Target: EpCAM (Epithelial Cell Adhesion Molecule)

Product Category: Antibody

This product provides basic information on antibody therapy candidates in research and development targeting EpCAM.

This product consists of:

• Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
• Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
• One-month online access to La Merie Publishing’s database for therapeutics and therapy candidates targeting EpCAM (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein mediating Ca2+-independent cell-cell adhesion in epithelia. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Additionally, EpCAM has oncogenic potential via its capacity to upregulate c-myc and cyclins A & E.

EpCAM is over-expressed in most of epithelial tumors including colon cancer (97.7%), gastric cancer (90.7%), prostate cancer (87.2%), and lung cancer (63.7%). The high-level expression of EpCAM in solid tumors has made it an attractive target for antibody molecules to treat epithelial cancers, particularly adenocarcinomas. However, EpCAM is also highly prevalent on normal cells.

EpCAM is a broadly expressed, validated anti-cancer target that to date has been limited in its development potential due to systemic, on-target off-tumor dose-limiting toxicities.

ADC target options are limited by normal tissue expression. Although EpCAM is an ideal cancer target, it has not been tractable by conventional approaches. Conditional activation can allow ADC technology and T-cell recruiting bispecific antibody technologies to be applied to a wider set of targets. Conventional EpCAM/CD3 bispecific antibodies have shown beneficial clinical outcomes in cancer patients, but have been hampered by dose limiting toxicities due to wide target distribution in normal tissues and potent T cell activation.